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Abstract
Objectives
To investigate the in vitro and ex-vivo effect of IL-6 inhibition on the balance between Th1, Th2, Th17 and Treg cells.
Methods
Ten consecutive adult patients with active early rheumatoid arthritis (ERA) and ten healthy volunteers were 
included in the study. The percentages of Th1, Th2, Th17 and Treg cells were analysed by flow cytometry in the peripheral 
blood mononuclear cells obtained from controls and from RA patients at the time of first evaluation and just before the 
third TCZ infusion. The in vitro effect of TCZ on the different subsets of CD4+ T cells and the expression levels of Th1, 
Th2, Th17 and Treg-related cytokines was also assessed.
Results
Treatment with TCZ, both ex vivo and in vitro, resulted in a significant reduction of the percentage of Th1, Th17 and Treg 
cells with a concomitant significant increase of Th2 cell subsets. The reduction of the different subsets of T lymphocytes was 
associated with an intense staining with Annexin V, suggesting an apoptotic-related cell reduction. A significant decrease of 
Th1, Th17 and Treg cytokines and a concomitant increase of IL-4 was also observed after TCZ treatment in PBMC isolated 
from RA patients.
Conclusions
TCZ could modify the immune imbalance in RA inducing apoptosis of Th1,  Th17 and Treg cells and promoting the 
appearance of a Th2 response.
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Introduction
IL-6 is a pleiotropic pro-inflammatory 
cytokine which is involved in the mod-
ulation of T cell proliferation, differen-
tiation, and apoptosis (1-3). IL-6 in fact 
regulates the balance between Th1 and 
Th2 cells (4) and, together with TGF-β, 
promotes the differentiation of naïve T 
cell in the highly pathogenic Th17 cell 
(5), while inhibiting the generation of 
regulatory T cell (Treg) (6). 
Rheumatoid arthritis (RA) is an autoim-
mune systemic inflammatory disorder 
that may affect many tissues and organs, 
but principally leads to inflammation of 
the joints and surrounding tissues. In 
RA, articular inflammation seems to be 
caused by the expression of inflamma-
tory cytokines and chemokines deter-
mining the activation and proliferation 
of the synovial lining and the recruit-
ment of inflammatory cells and B cell 
activation with autoantibody produc-
tion. Among several cytokines involved 
in RA pathogenesis, IL-6 has been 
demonstrated to promote synovial neo-
vascularisation, infiltration of inflam-
matory cells, and synovial hyperplasia 
leading to RA joint destruction. 
Blockade of IL-6 activity has been 
considered to be of both scientific and 
clinical interest in RA and tocilizumab 
(TCZ), a humanised anti-IL-6 receptor 
antibody, has been shown to be benefi-
cial in decreasing RA disease activity, 
slowing radiographic progression and 
improving function thus being consid-
ered an effective treatment for RA (7-9). 
Conflicting data have, however, emerged 
on Treg and Th17 behaviour during TCZ 
treatment in both mice (10) and humans 
(11) and the role of IL-6 inhibition on 
Th1 and Th2 subset of T effector cells 
remains to be also elucidated.
The aim of the present study was to 
evaluate the in vitro and ex vivo effect of 
IL-6 inhibition on the balance between 
CD4 T effector subsets and Treg cells. 
Patients and methods
Study population
Ten consecutive adult patients [8 fe-
males and 2 male; median ± Standard 
Deviation (SD) age 47 (3)] with active 
early rheumatoid arthritis (ERA) [me-
dian disease duration 7.5 (range 6–12 
months)], diagnosed accordingly to 
the 2010 American College of Rheu-
matology/European League Against 
Rheumatism (ACR/EULAR) criteria 
for rheumatoid arthritis (12) and ten 
sex- and age-matched healthy volun-
teers (NC) were included in the study. 
Four of the patients had an inadequate 
response to methotrexate (MTX) and 
6 failed to respond to an association of 
MTX and TNF-alpha blocking agents. 
Active disease was defined by at least 
6 swollen and tender joint count, a C- 
reactive protein (CRP) over 10 mg/l 
and/or an erythrocyte sedimentation 
rate (ESR) over 30 mm/h and a DAS28 
>3.8. All patients received low dose 
steroids (<7.5 mg daily prednisone). 
All participants gave their informed 
consent and the study was approved 
by the hospital ethics committee. TCZ 
was given intravenously at a dose of 8 
mg/kg at baseline and thereafter every 
4 weeks. 
Cell preparation, culture, 
and flow cytometry
Peripheral blood was obtained from 
controls and from ERA patients at the 
time of first evaluation and just be-
fore the third TCZ infusion. Periph-
eral blood mononuclear cells (PBMCs) 
were processed as previously described 
(13). The cells obtained at baseline 
(visit T0) were cultured in vitro with 
or without anti-IL-6R (Tocilizumab, 
Roche) (10 µg/ml) and incubated at 
37°C in 5% CO2 for 24h, 48h, and 72 
h. Twenty-four hours before stopping 
the culture, PMA (50 ng/ml) and iono-
mycin (1 μg/ml) were added followed 
by Brefeldin A, 2 hours later (1 μg/ml; 
Sigma St. Louis, MO). PBMCs were 
also obtained from patients at the time 
of the third infusion with TCZ, and 
considered already treated in vivo with 
TCZ and for this reason stimulated only 
with PMA (50 ng/ml) and ionomycin (1 
μg/ml) for 24 h. After incubation, cells 
were collected and stained with the fol-
lowing monoclonal antibodies (mAb) 
anti-human CD4-PerCP (BD Bio-
sciences, San Josè, CA), anti-human 
IFN-γ-PE (BD Biosciences, San Josè, 
CA), anti-human IL-17-APC (R&D 
system, Minneapolis, MN), anti-human 
IL-4-FITC (BD Biosciences, San Josè, 
CA), anti-human CD25-FITC APC 
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(BD Biosciences, San Josè, CA), anti-
human FoxP3-PE (BioLegend, SanD-
iego, CA). Isotype-matched irrelevant 
antibodies were used as a negative 
control. Total cells were incubated with 
mAbs for 30 min on ice and washed 
twice in PBS, cointaining 0.1% (w/v) 
NaN3. After surface staining, the cells 
were fixed with 1% (w/v) paraformal-
dehyde (Sigma) for 30 min at 4°C and 
then were permeabilised with a perme-
abilisation solution (BD Biosciences) 
for 10 minutes at room temperature and 
stained with antibodies to intracellular 
antigens for 30 min at 4°C.  Four colour 
flow cytometry analysis was performed 
using a FACSCalibur (BD Bioscienc-
es). At least 50,000 cells (events), gated 
on lymphocytes region, were acquired 
for each sample.
Aliquots of cells coming from in vitro 
experiments were incubated at 37°C 
5% CO2 for 72 hours to determine the 
percentage of dead cells utilising the 
Annexin V/PI kit (Roche). 
RNA isolation and quantitative 
real-time polymerase chain reaction 
(RT-PCR)
RNA was extracted from PBMCs iso-
lated from all the ERA patients, before 
and after 72 hours of in vitro treatment 
with TCZ as previously described (13). 
For quantitative TaqMan RT-PCR, 
master mix and TaqMan gene expres-
sion assays for GAPDH (glyceral-
dehyde 3-phosphate dehydrogenase) 
control, for IL-10 (Hs00174086_
m1), IL12 (Hs00168405_m1), IL-
17 (Hs00174383_m1) and IL-4 
(Hs00929862_m1)  were obtained from 
Applied Biosystems. 
Statistical analysis
The Mann Whitney U-test was used to 
compare paired patients before and af-
ter treatment and to compare patients 
before treatment (active RA) with the 
control group. One way Anova was 
used to compare whether the in vitro 
treatment with TCZ modified the per-
centage of T cell subsets at different 
time points. Results were expressed as 
median ± standard deviation (SD) and 
were considered statistically significant 
when p<0.05. All tests were two-tailed. 
Data are presented as histogrammes.
Results
An increase in Th1 and Th17 and 
a decrease in Treg occur in active 
RA patients  
Clinical characteristics of patients are 
summarised in Table I. We first as-
sessed the percentages of the different 
subsets of T-effector lymphocytes in 
ERA patients and in normal controls. 
As expected, a significant increase 
in the percentage of circulating Th17 
(CD4+/IFN-γ-/IL-17+) (6.5±0.4 in ERA 
and 3±0.3 in controls, p<0.004). and 
Th1 effector cells (CD4+/IFN-γ+/IL-
17) (9±0.8 in ERA and 3 ± 0.3  in con-
trols, p<0.004) was observed in ERA 
patients. Conversely, the percentage of 
Treg, defined as CD4+/CD25+/Foxp3+ 
cells, was significantly reduced in ac-
tive ERA patients compared to controls 
(0.7±0.12 vs. 1.5±0.18, p<0.006). The 
percentage of Th2 cells (CD4+/IL-4+) 
was not different between patients and 
controls (3.03±0.4 vs. 3.18±0.3, p=ns), 
confirming the predominance of Th1/
Th17 polarisation in ERA patients.
Effect of TCZ treatment on 
ERA  patients
After three months of therapy all pa-
tients were in remission (DAS28 <2.6). 
As shown in Figure 1a, treatment with 
TCZ resulted in a significant reduc-
tion of the percentage of Th1 (9±0.8 
vs. 3.4±0.2 p<0.004), Th17 (6.5±0.4 
vs. 2.7±0.3, p<0.003) and Treg cells 
(0.7±0.12 vs. 0.35±0.06, p<0.02). On 
the other hand a significant increase in 
the percentage of Th2 cells (4.5±0.29 
vs. 3.03±0.4, p<0.01) was observed in 
TCZ-treated patients. 
In agreement with the variations of 
the percentages of the different sub-
sets observed after TCZ therapy by 
flow cytometry, rt-PCR analysis dem-
onstrated that TCZ treatment induced 
a significant reduction of the expres-
sion levels of IL-10 (0.7±0.04 vs. 
0.2±0.04, p<0.02), IL-12 (1±0.08 vs. 
0.4±0.04, p<0.003) and IL-17 (1±0.12 
vs. 0.47±0.04,  p<0.007). A signifi-
cant increase in the expression of IL-4 
(0.8±0.04 vs. 0.4±0.05, p<0.006) also 
followed TCZ treatment (Fig. 1b). 
In vitro experiments  
The effect of TCZ on PBMCs was also 
investigated in in vitro studies. Incuba-
tion of PBMC with TCZ determined a 
significant time dependent decrease in 
the percentage of Th1 and Th17 in both 
patients and  controls at  24h, 48h and 
72h respectively. Treg cells showed a 
time dependent response to TCZ with 
an initial rapid increase occurring af-
ter 24-hour incubation, followed by a 
rapid decrease to baseline levels after 
48–72 hour in both patients and con-
trols. On the other hand a progressive 
increase of Th2 lymphocytes after TCZ 
incubation was observed in both pa-
tients and controls (Fig. 2a). 
Finally TCZ incubation (Fig. 2b-c) 
resulted in a significant increase of 
apoptotic cells in Th1 (6.7±0.5 vs. 
2.1±0.9 p<0.05), Th17 (4,1±0.6 vs. 
1±0.4 p<0.05) and Treg (0.98±0.1 vs. 
0.2±0.9, p<0.05) compartments but not 
in Th2 cells (0.5±0.7 vs. 0.6±0.9 p=ns). 
Discussion
Rheumatoid arthritis (RA) is a chronic 
inflammatory disease characterised 
by the imbalance between effector 
and regulatory T cells (14). Among 
the various cytokines involved in im-
mune regulation, IL-6 seems to play a 
fundamental role in the pathogenesis 
Table I. Baseline characteristics of RA patients and control subjects.
 Controls RA patients
 (N=10) (N=10)
Age (years) (SD) 50 (5) 47 (3)
Female (%) 100 80
Disease duration (years), median (SD) NA 7.5 (2.2)
DAS-28 CRP, median (SD) NA 6 (1.3)
HAQ, median (SD) NA 2 (0.8)
CRP (mg/l), median (SD) NA 4 (1.6)
ESR mm/h, median (SD) NA 53 (17)
RF, frequency, conc. (UI/L) (range) NA 60 [84 (34-204)]
Anti-CCP, frequency, conc. (UI/L) (range) NA 70 [120 (56-345)]
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Fig. 2. In vitro effect of tocilizumab (TCZ) therapy in patients with early rheumatoid arthritis (ERA). A. Mean percentage of different CD4 T cell subsets, 
obtained from ERA patients before TCZ therapy, treated in vitro with TCZ and analysed at different time points.  B. Viable cells (annexin-V− PI− (14%)); 
non-viable, including late apoptotic or necrotic cells (annexin-V+PI+(80%) or annexin-V− PI+(2.7%)); and apoptotic cells (annexin-V+ PI−(3.3%)) were de-
tected on lymphocyte region. C. Percentage of CD4 T cell subsets evaluated on viable cells region (annexin-V− PI−) represented as a histogramme. * p<0.05.
Fig. 1. Ex vivo effect of tocilizumab (TCZ) therapy in patients with early rheumatoid arthritis. A. Mean percentage of different CD4 T cell subsets in 
peripheral blood of ERA patients before and after 3 month of TCZ therapy. B. Relative mRNA quantification of IL-12, IL-17, IL-4, IL-10 was assessed by 
quantitative reverse transcriptase PCR in PBMC obtained from patients before and after 3 month of therapy. *p<0.05.
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of RA regulating the balance between 
pathogenic and protective T effector 
cells, modulating cell proliferation, 
differentiation, and apoptosis (6, 15). 
Since the important immunological 
role of IL-6, its block appears to be an 
effective therapeutic strategy for the 
treatment of rheumatoid arthritis. IL-6 
block could in fact result in restoring 
the immune balance in RA patients as 
suggested by a recent study demon-
strating that treatment with TCZ was 
able to restore the imbalance between 
Th17 and Treg cells (11). 
In our study a significantly in vivo and 
in vitro exposure to TCZ induced a 
profound depletion of Th1, Th17 and 
Treg lymphocytes and their related 
cytokines (IL-12, IL-17, IL-10). This 
immunologic effect seems to be related 
to the capacity of TCZ in inducing late 
apoptosis of Th1/Th17 and Treg cell 
subsets, as suggested by the intense 
staining for annexin V we observed 
after in vitro exposure of PBMC of 
patients and controls to TCZ. In agree-
ment with this hypothesis is, in our 
opinion, the demonstration that IL-6 
inhibits the Fas-mediated death of T 
cells (16) and that blocking of IL-6 in 
Crohn’s disease patients results in the 
intense apoptosis of lamina propria T 
lymphocytes (17).
These results are partially different 
from a recent study demonstrating a 
significant increase of Treg cell subset 
in RA patients after TCZ therapy (11). 
Indeed we observed, only a transient 
early increase in Treg expression in 
vitro experiments and it is not possible 
to exclude that an initial expansion of 
Treg could also occur in the early phase 
of in vivo TCZ treatment contributing 
to limiting the inflammation in RA. 
This effect, however, accordingly to 
our results, could be not relevant in the 
late phases of treatment. 
Interestingly, we also demonstrated 
that the apoptotic-dependent reduction 
of Th1/Th17/Treg cells was accompa-
nied by an increase of the percentage 
of Th2 cells and an enhanced expres-
sion of IL-4, an important Th2-related 
cytokine. This different immunologic 
behaviour could be explained by the 
different response of activated Th1 
and Th2 cells to the Fas-mediated ap-
optosis, since that this form of apop-
tosis may suppress Th1 but not Th2 
cells (18, 19). In addition, since that 
Th1 cells inhibit the proliferation, and 
therefore the development of Th2 cells, 
we cannot exclude that the reduction of 
Th1 response by TCZ may directly fa-
vour a Th2 polarisation.
In conclusion our study supports pre-
vious results on the protective mecha-
nisms of IL-6 blockade in RA that in-
dicates a role of TCZ in the down-reg-
ulation of Th1/Th17 helper responses 
and suggests that the expansion of Th2 
cells could represent a relevant im-
munologic mechanism contributing to 
the resolution of inflammation in TCZ-
treated RA patients. 
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